<code id='A7F7DE2BFB'></code><style id='A7F7DE2BFB'></style>
    • <acronym id='A7F7DE2BFB'></acronym>
      <center id='A7F7DE2BFB'><center id='A7F7DE2BFB'><tfoot id='A7F7DE2BFB'></tfoot></center><abbr id='A7F7DE2BFB'><dir id='A7F7DE2BFB'><tfoot id='A7F7DE2BFB'></tfoot><noframes id='A7F7DE2BFB'>

    • <optgroup id='A7F7DE2BFB'><strike id='A7F7DE2BFB'><sup id='A7F7DE2BFB'></sup></strike><code id='A7F7DE2BFB'></code></optgroup>
        1. <b id='A7F7DE2BFB'><label id='A7F7DE2BFB'><select id='A7F7DE2BFB'><dt id='A7F7DE2BFB'><span id='A7F7DE2BFB'></span></dt></select></label></b><u id='A7F7DE2BFB'></u>
          <i id='A7F7DE2BFB'><strike id='A7F7DE2BFB'><tt id='A7F7DE2BFB'><pre id='A7F7DE2BFB'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:Wikipedia    - browse:68324

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge